Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Positive Vaccine-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of DTcP in Infants and Children at 2 and 3 Months of Age

NCT05951725 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT05951725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Positive Vaccine-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of DTcP in Infants and Children at 2 and 3 Months of Age
Lead sponsor
CanSino Biologics Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 11, 2023
Completion date
April 1, 2025
Enrollment
2,520 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, tetanus and acellular pertussis